$MGTX on NASDAQ
March 14, 2024
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
February 13, 2024
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
December 21, 2023
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
November 21, 2023
MeiraGTx to Participate in Upcoming Investor Conferences
November 14, 2023
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
October 30, 2023
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
October 24, 2023
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
August 10, 2023
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 01, 2023
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
July 19, 2023
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
June 27, 2023
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
June 22, 2023
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023
May 16, 2023
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 11, 2023
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 03, 2023
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
April 21, 2023
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 20, 2023
MeiraGTx to Participate in Upcoming Investor Conferences
March 14, 2023
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
December 13, 2022
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 08, 2022
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
November 22, 2022
MeiraGTx to Participate in Upcoming Investor Conferences
November 10, 2022
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
October 04, 2022
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 01, 2022
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
September 16, 2022
MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government
September 08, 2022
MeiraGTx to Participate in Upcoming Investor Conferences
August 11, 2022
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
August 03, 2022
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities
June 28, 2022
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control
May 12, 2022
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
May 04, 2022
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
April 27, 2022
MeiraGTx Appoints Debra Yu, MD to Board of Directors
April 19, 2022
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
March 10, 2022
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
January 27, 2022
MeiraGTx Receives Clinical Development Milestone Payment from Janssen
December 14, 2021
MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
December 07, 2021
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
November 29, 2021
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation
November 10, 2021
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
November 09, 2021
MeiraGTx to Participate in Upcoming Virtual Investor Conferences
October 19, 2021
MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platform at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress
September 28, 2021
MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
September 09, 2021
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa
August 11, 2021
MeiraGTx Reports Second Quarter 2021 Financial and Operational Results
May 11, 2021
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
May 05, 2021
MeiraGTx Announces Participation at Upcoming Investor Conferences
April 19, 2021
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
March 11, 2021
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
March 04, 2021
MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
January 26, 2021
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
- No Recent Filings Found.
